There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Silence Therapeutics (SLN – Research Report) and Warby Parker (WRBY – Research Report) with bullish sentiments.
Discover the Best Stocks and Maximize Your Portfolio:
Silence Therapeutics (SLN)
William Blair analyst Myles Minter maintained a Buy rating on Silence Therapeutics today. The company’s shares closed last Thursday at $4.84, close to its 52-week low of $4.06.
According to TipRanks.com, Minter is a 4-star analyst with an average return of 6.8% and a 45.6% success rate. Minter covers the Healthcare sector, focusing on stocks such as Entrada Therapeutics Inc, Axsome Therapeutics, and Verve Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Silence Therapeutics with a $50.40 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Warby Parker (WRBY)
In a report released today, Dylan Carden from William Blair maintained a Buy rating on Warby Parker. The company’s shares closed last Thursday at $24.95.
According to TipRanks.com, Carden is a 4-star analyst with an average return of 23.7% and a 64.4% success rate. Carden covers the NA sector, focusing on stocks such as National Vision Holdings, Abercrombie Fitch, and Revolve Group.
Currently, the analyst consensus on Warby Parker is a Moderate Buy with an average price target of $26.42, a 9.8% upside from current levels. In a report issued on February 20, BTIG also maintained a Buy rating on the stock with a $30.00 price target.
Read More on SLN: